Drug intelligence / Profile preview

Tim-3 small molecule inhibitor

Development stage
Preclinical
Modality
Small Molecules
01

Overview

A Tim-3 small molecule inhibitor is a class of small molecule compounds designed to target and inhibit T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3), an immune checkpoint receptor. Tim-3 is expressed on various immune cells, including T cells, natural killer (NK) cells, and macrophages. In the context of pulmonary fibrosis, Tim-3 inhibition has been shown to regulate macrophage polarization, specifically suppressing the activation of Stat3 signaling pathways, which in turn inhibits the activation and proliferation of fibroblasts. In oncology, small molecule inhibitors of Tim-3 block its interaction with ligands such as galectin-9, phosphatidylserine (PtdSer), HMGB1, and CEACAM1, thereby restoring T-cell and NK-cell function and enhancing anti-tumor immunity.

Other names
TIM-3 small molecule inhibitorTIM3 small molecule inhibitorTIM 3 small molecule inhibitorTIM-3 small-molecule inhibitorTIM3 small-molecule inhibitorTIM 3 small-molecule inhibitor
02

Targets

CEACAM1LGALS9 (Galectin-9)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)HMGB1 (High mobility group protein B1)STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on Tim-3 small molecule inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tim-3 small molecule inhibitor.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call